secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K/A
Filed at:   2023-07-14T23:59:59+00:00
Accession:  0001213900-23-057137
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma gets Nasdaq extension to comply with equity rule; deadline August 31, 2023
--------------------------------------------------------------------------------

- Received deficiency letter on May 26, 2023 for non-compliance with minimum stockholders' equity requirement.
- Nasdaq granted extension on July 10, 2023 to comply with Listing Rule 5550(b)(1) by August 31, 2023.
- Failure to evidence compliance upon filing Q3 2023 periodic report may lead to delisting from Nasdaq.
- Common stock continues trading under symbol ABVC on Nasdaq Capital Market while appeal rights exist.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023057137/0001213900-23-057137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023057137/ea181759-8ka1_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-057137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer